NAVAMEDIC Aktie

 

Oslo, 3 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 12 June 2025, regarding notice of an extraordinary general meeting in connection with, inter alia, a private placement (including a loan conversion to be completed by Navamedic ASA) and a contemplated subsequent offering in the Company. The extraordinary general meeting was held today, on 3 July 2025, at 14:00 hours (CEST). All resolutions proposed by the Company's board of directors were approved, including (i) the issuance of 56,...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 29 June 2025 - Reference is made to the stock exchange announcement made by Navamedic ASA (the "Company" or "Navamedic", and...

OSLO, Norway, June 27, 2025 /PRNewswire/ -- Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use with a medicinal product. "OraFID® is a unique,......

OSLO, Norway, June 24, 2025 /PRNewswire/ -- Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") yesterday, on June 23, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne......

Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") yesterday, on June 23, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS. Navamedic will today, on Tuesday 24 June 2025, host two online presentations, at 12:00 CEST (in Norwegian) and 13:00 CEST (in English). The presentations will be held by the Company's CEO, Kathrine Gamborg Andreassen and CFO, Lars Hjarrand. To attend the webcast, please send an e-mail to ca@dnbcarnegie.no. The material to be presented in...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") earlier today, on...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER......

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") earlier today, on...

Oslo, 4 June 2025: The Annual General Meeting of Navamedic ASA was held today at 09:00 CEST. All items on the agenda were resolved in accordance with the board of directors' proposals and the nomination committee's recommendations. A copy of the minutes from the Annual General Meeting is attached to this notice and will also be made available on the Company's webpage www.navamedic.com. This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For further information, please contact: Kathrine G. Andreassen, CEO,...

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Wednesday, June 4th 2025 at 09:00 (CET) in the Navamedic offices in Henrik Ibsens gate 100, 0255 Oslo. The Notice of the Annual General Meeting is attached. The Notice is posted electronically or by mail to all shareholders and is available on the company's website at https://navamedic.com/investors/general-meeting/. For further information, please contact: Kathrine G. Andreassen, CEO, Navamedic, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, Navamedic, Mobile: +47 917 62 842 E-mail:...

Oslo, 05 May 2025 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, today announced it has launched Eroxon®, a clinically proven over-the-counter topical treatment for the treatment of erectile dysfunction in men, in Denmark. The product launch marks the fourth launch of Eroxon® in the Nordics since Navamedic introduced the product to the Norwegian market in February 2024. As part of Navamedic's Consumer Health area, Eroxon® will be available to Danish consumers, without...

OSLO, Norway, April 30, 2025 /PRNewswire/ -- Navamedic ASA has today published its Annual Report for 2024. Find enclosed the report in PDF as well as an ESEF file version. The report is also made available at the company's website at https://navamedic.com/investors/annual-reports/ For......

Oslo, April 30 2025 -  Navamedic ASA has today published its Annual Report for 2024. Find enclosed the report in PDF as well as an ESEF file version. The report is also made available at the company's website at    https://navamedic.com/investors/annual-reports/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com About Navamedic: Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing...

OSLO, Norway, April 30, 2025 /PRNewswire/ -- In the first quarter of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, reported revenues of NOK 132.0 million,......

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) today announced it has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement. "It is a......

Oslo, April 28, 2025 - Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2025 results on Wednesday, April 30, 2025. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial -results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.com...

Oslo, April 10[th], 2025 – Observe Medical ("the Company" or "Observe Medical") have reached agreements in principle with Convatec and Navamedic to reduce their debt position from in total NOK 82 million to NOK 41 million, with an adjusted payment plan for the remaining debt. Such debt reduction is conditional upon injection of new equity in the minimum amount of NOK 25 million. The Company has also been in constructive dialogue with existing shareholders and new investors who have indicated willingness to contribute equity in an amount of NOK 25 million, subject to debt reductions being...

Oslo, Norway – [2025.04.01] – Navamedic is pleased to announce that the European Medicines Agency's (EMA) human medicines committee (CHMP) has concluded its review of Mysimba (naltrexone/bupropion), affirming that the benefits of the medicine continue to outweigh its risks for weight management in adults with obesity or overweight. The CHMP has determined that there are no cardiovascular safety concerns for Mysimba when used for up to 12 months. The CHMP has agreed that an ongoing safety study with Mysimba in patients with obesity or overweight is appropriate to generate evidence about this...

Oslo, 17 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final results of the subsequent offering in the Company and the waiver of the condition for completion of the share capital increase of NOK 10,630,629.88, through the issuance of 40,887,038 new shares to Navamedic ASA, at a subscription price of 0.40 per share, in connection with the conversion by Navamedic ASA of a loan amount of NOK 16,354,815.20 under a loan from Navamedic ASA to the Company (the "Loan Conversion")...

Oslo, 5 December 2024: Reference is made to the stock announcement published by Observe Medical ASA (the "Observe Medical") on 5 December 2024 regarding the final result of the subsequent offering and the partial conversion to shares of certain loans from Navamedic ASA ("Navamedic") to Observe Medical. Navamedic currently holds 4,222,727 shares in Observe Medical, equal to approx. 1.72% of the current shares and votes in Observe Medical. Following the issuance and registration of the shares in both the subsequent offering and the shares to be issued to Navamedic in connection with the...